Combining an Effective Rule-based Chatbot With ChatGPT-supported Real-time Question-answer Functions to Promote Seasonal Influenza Vaccination Among Community-dwelling People Aged 65 Years and Above
Combining an Effective Rule-based Chatbot With ChatGPT-supported Real-time Question-answer Functions to Promote Seasonal Influenza Vaccination Among Community-dwelling People Aged 65 Years and Above: a Partially Blinded Randomized Controlled Trial
This study is a partially blinded (outcome assessors and data analysts) and parallel-group randomized controlled trial. Community-dwelling people aged ≥65 years who have not received the SIV for the approaching flu season will be randomized evenly (1:1) into either the intervention group or the control group. During the intervention period, the intervention group will have access to the hybrid combination of a rule-based chatbot (SIV-Chatbot) with the ChatGPT-supported real-time Question & Answer (QA) functions, while the control group will have access only to the SIV-Chatbot.
The SIV-Chatbot will deliver the same interventions for both groups. The number of intervention sessions (four) and timing (week 0, 2, 4 & 6) will also be the same. In the intervention group, the hybrid Chatbot will invite the participants to raise open-ended questions related to SIV using flexible methods (such as voice messages, typing with keyboards, or handwriting) at each session. The ChatGPT will answer these questions immediately in the format of text messages. The functions can be used repeatedly throughout the intervention period (weeks 0-6), and participants will be free to spend as much time as they want on such functions.
Telephone interviews will be conducted at baseline (T0), after completion of the intervention (T1), and six months after T1 (T2). The primary outcome will be the self-reported SIV uptake measured at T2. The research team will validate that outcome by requesting the participants upload an image of their SIV receipt, while hiding their personal identification, via the WhatsApp account used in this study.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Zixin Wang, PhD
- Número de telefone: +852 22528474
- E-mail: wangzx@cuhk.edu.hk
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- aged ≥65 years
- possession of a Hong Kong ID
- able to speak and comprehend Cantonese
- have a smartphone with internet access
- have either installed or are willing to install WhatsApp on their smartphone
- have not taken seasonal influenza vaccination for the approaching flu season
Exclusion Criteria:
- score ≤16 in the validated telephone version of the Cantonese Mini-Mental State Examination (T-CMMSE)
- either blindness or deafness
- with known contraindications to the SIV as indicated by the Hong Kong Centre for Health Protection (e.g., history of severe allergic reactions to any of the vaccine component or a previous dose of SIV and bleeding disorders)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intervention group
Have access to the hybrid combination of a rule-based chatbot (SIV-Chatbot) with the ChatGPT-supported real-time QA functions |
After assessing participants' stage of change (SOC) regarding SIV uptake, the rule-based component (SIV-Chatbot) will deliver online interventions tailored to their current SOC. There will be four intervention sessions at week 0, 2, 4 and 6. In addition, the hybrid Chatbot will invite the participants to raise open-ended questions related to SIV using flexible methods at each session. The ChatGPT will answer these questions immediately in the format of text messages. The functions can be used repeatedly throughout the intervention period (weeks 0-6), and participants will be free to spend as much time as they want on such functions. |
|
Comparador Ativo: Control group
Have access only to a rule-based chatbot (SIV-Chatbot) |
After assessing participants' stage of change (SOC) regarding SIV uptake, the rule-based chatbot (SIV-Chatbot) will deliver online interventions tailored to their current SOC. There will be four intervention sessions at week 0, 2, 4 and 6. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Uptake of seasonal influenza vaccination
Prazo: Six months after completion of the intervention
|
The primary outcome will be the self-reported seasonal influenza vaccination uptake measured at T2 (six months after completion of the intervention). The research team will validate that outcome by requesting the participants upload an image of their receipt. |
Six months after completion of the intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Stage of change related to seasonal influenza vaccination uptake
Prazo: T0 (baseline), T1 (after completion of intervention), and T2 (six months after completion of the intervention)
|
Participants' SOC will be measured at T0 (baseline), T1 (after completion of intervention), and T2 (six months after completion of the intervention) by using validated questions |
T0 (baseline), T1 (after completion of intervention), and T2 (six months after completion of the intervention)
|
|
Knowledge and attitudes related to seasonal influenza vaccination
Prazo: T0 (baseline) and T2 (6 months after completion of the intervention)
|
Knowledge and attitudes will be measured at T0 (baseline) and T2 (6 months after completion of the intervention) by validated tools |
T0 (baseline) and T2 (6 months after completion of the intervention)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- GRF14611325
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data presented in this study are available from the corresponding author upon request. The data are not publicly available as they contain sensitive personal information.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .